ANI announced that the Food and Drug Administration (FDA) has approved Oxcarbazepine Tablets, the generic version of Novartis‘ Trileptal. In addition, ANI announced the launch of Oxycodone HCl Capsules.
Oxcarbazepine is an antiepileptic indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults, and as monotherapy in the treatment of partial seizures in children aged ≥4 years with epilepsy, and as adjunctive therapy in children aged ≥2 years with partial seizures.
Oxycodone HCl is a CII controlled substance indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate. ANI was approved for Oxycodone HCl Capsules in April 2016.
ANI’s Oxcarbazepine Tablets will be available in 150mg, 300mg, and 600mg strengths. Oxycodone HCl Capsules are available in a 5mg strength.
For more information call or visit AniPharmaceuticals.com.